Acquisition

RNS Number : 5498W
Smith & Nephew Plc
17 April 2019
 

Smith & Nephew Completes Acquisition of Leaf Healthcare, Inc.

17 April 2019

 

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Leaf Healthcare, Inc., the developer of the unique Leaf Patient Monitoring System to monitor the orientation and activity of patients susceptible to pressure ulcers. The transaction follows Smith & Nephew's successful two-year partnership with Leaf Healthcare as an exclusive distributor and strategic investor.

The Leaf Patient Monitoring System is a small, lightweight, wearable sensor that wirelessly monitors a patient's position and their mobility whilst in hospital. The tracking data is used to automate and document compliance with prescribed turn protocols for patients at risk of pressure injuries1. Leaf, together with Smith & Nephew's ALLEVYN LIFE and ALLEVYN GENTLE BORDER and SECURA Skin Care products, offers customers a portfolio to help optimise pressure injury prevention protocols.

The commercial terms of the acquisition have not been disclosed. Leaf is currently only available in the US.

 

ENDS

Enquiries

Investors

Andrew Swift                                    +44 (0) 20 7960 2285
Smith & Nephew

Media

Charles Reynolds                             +44 (0) 1923 477314
Smith & Nephew

About Smith & Nephew

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on TwitterLinkedIn or Facebook.

References

1.    Pickham, D., Pihulic, M., Valdez, A., et al. Pressure injury prevention practices in the ICU: Real-world data captured by wearable patient sensors. Wounds. 2018.

For detailed product information, including indications for use for use, contraindications, precautions and warnings, please consult each products Instructions for Use (IFU) prior to use.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEAKLXFFPNEFF
UK 100

Latest directors dealings